---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122337"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:38:41.989804+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics Q3 net loss $32.3M; PRT3789 shows partial responses in SMARCA4-mutated cancers

## Summary
- Cash, equivalents and marketable securities $153.6M; net loss $32.3M ($0.43/share) vs $30.6M prior year.
- PRT3789 Phase 1: 4 confirmed partial responses in 26 evaluable SMARCA4-mutated NSCLC/esophageal patients; combo with docetaxel safe.
- Initiated Phase 1 trial of oral SMARCA2 degrader PRT7732 in biomarker-selected SMARCA4-mutated cancers.
- PRT2527 interim Phase 1 data in hematological malignancies to be presented at ASH Dec 2024; dose escalation completing this year.
- Entered collaboration with Pfizer Ignite for SMARCA2 degrader development; Prelude retains full ownership.

## SEC filing metadata
- accession: 0000950170-24-122337
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017024122337/0000950170-24-122337-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017024122337/prld-20241106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122337
- JSON: https://secwatch.observer/filing/0000950170-24-122337.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122337.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.